BeyondSpring Inc. Ordinary Shares (BYSI)
Stock · NASDAQ · Health Care
$0.559as of 10/16/2026
Price chart
Active signals
BYSI Signal Track Record
How signals performed across all stocks →What BYSI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -3.9% | 46% | September 28, 2026 |
| Bollinger Band Breakdown | 22 | -3.6% | 41% | August 6, 2026 |
| Bollinger Band Breakout | 21 | -8.0% | 33% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -1.6% | 38% | June 26, 2026 |
| Any 20-session window (baseline) | -5.0% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment o…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 44
Fundamentals
- 1-day range
- $0.722$0.7838
- Market cap
- $35.77M
- P/E (trailing)
- —
- P/E (forward)
- -1.61
- EPS (trailing)
- $-0.16
- Dividend yield
- —
- Beta
- -0.26
- Avg. volume
- 851.5K
BeyondSpring Inc. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- BYSIBeyondSpring Inc. Ordinary Shares$0.559▼ 3.95%Market cap $35.77MP/E —$0.5657$2.44
- NNVCNanoViricides Inc. Common Stock$1.38▲ 0.73%Market cap $35.56MP/E —$0.85$2.23
- LTRNLantern Pharma Inc. Common Stock$0.668▲ 0.15%Market cap $35.47MP/E —$0.651$4.58
- SERSerina Therapeutics Inc. Common Stock$1.72▼ 3.91%Market cap $35.24MP/E —$1.22$5.29
- VERUVeru Inc. Common Stock$2.3▼ 5.74%Market cap $37.08MP/E —$2.05$7.33
- IXHLIncannex Healthcare Inc. Common Stock$2.82▼ 2.08%Market cap $37.21MP/E —$2.49$14.91
- CRVOCervoMed Inc. Common Stock$2.24▼ 0.44%Market cap $37.33MP/E —$2.13$10
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BYSI BeyondSpring Inc. Ordinary Shares | $35.77M | — | $0.559 | ▼ 3.95% | $0.5657$2.44 |
| NNVC NanoViricides Inc. Common Stock | $35.56M | — | $1.38 | ▲ 0.73% | $0.85$2.23 |
| LTRN Lantern Pharma Inc. Common Stock | $35.47M | — | $0.668 | ▲ 0.15% | $0.651$4.58 |
| SER Serina Therapeutics Inc. Common Stock | $35.24M | — | $1.72 | ▼ 3.91% | $1.22$5.29 |
| VERU Veru Inc. Common Stock | $37.08M | — | $2.3 | ▼ 5.74% | $2.05$7.33 |
| IXHL Incannex Healthcare Inc. Common Stock | $37.21M | — | $2.82 | ▼ 2.08% | $2.49$14.91 |
| CRVO CervoMed Inc. Common Stock | $37.33M | — | $2.24 | ▼ 0.44% | $2.13$10 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Majeti Jiangwen · July 1, 2026 · Grant100.0K
- Qiu Min · July 1, 2026 · Grant100.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
BYSI Discusses FDA Fast Track Designation for Plinabulin
BeyondSpring reported that the FDA has granted Fast Track designation to its drug Plinabulin for use after immune checkpoint inhibitor therapy in non‑squamous non‑small cell lung cancer. The company also mentioned a strategic transaction related to the program. The announcement appears alongside recent pre‑market and after‑hours activity that highlighted BYSI among active health‑care stocks.
BYSI Discusses FDA Fast Track Designation for Plinabulin. BeyondSpring reported that the FDA has granted Fast Track designation to its drug Plinabulin for use after immune checkpoint inhibitor therapy in non‑squamous non‑small cell lung cancer. The company also mentioned a strategic transaction related to the program. The announcement appears alongside recent pre‑market and after‑hours activity that highlighted BYSI among active health‑care stocks.